CP
Therapeutic Areas
Integral Molecular Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CLDN18.2 x CD3 TCE / CAR-T | Solid tumors (gastric, pancreatic) | Preclinical |
| GPRC5D x CD3 TCE | Multiple myeloma | Preclinical |
| CCR8 ADC | Immuno-oncology | Preclinical |
| CLDN18.2 ADC | Solid tumors | Preclinical |
| Undisclosed Program | Oncology | Phase 1 |